By Christopher Morrison
Sharing just isn’t what it used to be.
Share the Wealth? No Thanks
Biopharmaceutical companies are doing the math and increasingly coming to one conclusion: it's in their economic interests to buy out a biotech partner. Genentech Inc.'s $919 million all-cash acquisition of its omalizumab (Xolair) partner Tanox Inc. in November is one of the most recent examples.
More from Business Strategy
More from In Vivo
• By
In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.
video
Sponsored by:
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG
• By
Understand who’s influencing access decisions and how pharma can engage strategically across the continent.